Baciderm (Ointment, Powder) Instructions for Use
ATC Code
D06AX (Other antibiotics for topical use)
Active Substances
Bacitracin (Rec.INN registered by WHO)
Neomycin (Rec.INN registered by WHO)
Clinical-Pharmacological Group
A drug with antibacterial action for external use
Pharmacotherapeutic Group
Antibiotics and antimicrobial agents used in dermatology; antibiotics for topical use; other antibiotics for topical use
Pharmacological Action
A combined antibacterial agent for external use. It contains two antibiotics that have a bactericidal effect, Neomycin and Bacitracin.
Bacitracin is a polypeptide antibiotic that inhibits the synthesis of the bacterial cell wall. Bacitracin is particularly active against gram-positive microorganisms, such as β-hemolytic streptococci, staphylococci, and some gram-negative pathogens. Resistance to bacitracin is extremely rare.
Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis. Active against gram-positive and gram-negative bacteria.
Due to the use of a combination of these two antibiotics, a broad spectrum of action of this agent and a synergism of action against a number of microorganisms, for example, staphylococci, is achieved.
Pharmacokinetics
The active substances are generally not absorbed (even through damaged skin); nevertheless, high concentrations of them are present in the skin.
The tissue tolerance of this combination is considered excellent; inactivation by biological products, blood, and tissue components is not observed.
Indications
It is used in appropriate dosage forms for the treatment and prevention of infections caused by microorganisms sensitive to neomycin and/or bacitracin: bacterial skin infections of limited prevalence, including boils, carbuncles (after surgical treatment), staphylococcal sycosis, periporitis, deep folliculitis, suppurative hidradenitis, paronychia, contagious impetigo, infected trophic ulcers of the lower extremities, infected eczema, bacterial diaper dermatitis, bacterial complications of viral infections caused by Herpes simplex or Herpes zoster (including infection of vesicles in chickenpox); prevention of umbilical infection in newborns; prevention of infection after surgical procedures, for additional treatment in the postoperative period (after tissue excision, cauterization, episiotomy, treatment of fissures, perineal rupture, weeping wounds and sutures), in cosmetic surgery, during skin transplantation.
ICD codes
| ICD-10 code | Indication |
| B01.8 | Varicella with other complications |
| B02.8 | Herpes zoster with other complications |
| I83.2 | Varicose veins of lower extremities with ulcer and inflammation |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| L22 | Diaper dermatitis |
| L30.3 | Infectious dermatitis (infectious eczema) |
| L73.2 | Hidradenitis suppurativa |
| L73.8 | Other specified follicular disorders (sycosis barbae) |
| L73.9 | Disease of hair follicles, unspecified |
| L98.4 | Chronic skin ulcer, not elsewhere classified |
| O70 | Perineal laceration during delivery |
| P38 | Omphalitis of newborn with or without mild hemorrhage |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| Z29.2 | Other prophylactic chemotherapy (administration of antibiotics for prophylactic purposes) |
| Z94.6 | Presence of transplanted bone |
| ICD-11 code | Indication |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1C44 | Non-pyogenic bacterial infections of skin |
| 1E90.Z | Varicella, unspecified |
| 1E91.Z | Herpes zoster, unspecified |
| BD74.Z | Chronic venous insufficiency of lower extremities, unspecified |
| EA40 | Tropical phagedenic ulcer |
| EA50.3 | Staphylococcal scarlet fever |
| EA88.0Z | Infectious dermatitis, unspecified |
| EB21 | Pyoderma gangrenosum |
| ED81 | Acneiform inflammatory disorders |
| ED81.0 | Pustular atrophic folliculitis of the scalp |
| ED91.0 | Heterotopia of sebaceous glands |
| ED91.1 | Hyperplasia of sebaceous glands |
| ED91.2 | Seborrhea |
| ED92.0 | Hidradenitis suppurativa |
| ED9Y | Other specified disorders of the hair follicle |
| EF60 | Ischemic ulceration of the skin |
| EG30.0 | Folliculitis of the scalp |
| EH40.10 | Diaper dermatitis |
| EM0Z | Unspecified skin disorder |
| JB09.Z | Perineal laceration during delivery, unspecified |
| KA65.1 | Omphalitis of newborn |
| ME60.2 | Ulcerative skin lesion of unspecified nature |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| QB63.5 | Presence of transplanted bone |
| QC05.Y | Other specified prophylactic measures |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Apply a thin layer of ointment or a light dusting of powder to the affected skin area two to three times daily.
Cleanse and dry the affected area thoroughly before each application.
For minor wounds, burns, and abrasions, apply the preparation and cover with a sterile bandage if necessary.
For infected dermatoses such as impetigo or infected eczema, apply directly to the lesions.
In post-surgical wound care, apply to the suture line or graft site to prevent infection.
The duration of treatment is typically 5 to 7 days; do not use for more than 10 days unless directed by a physician.
For prevention of umbilical infection in newborns, apply a small amount to the umbilical stump until it heals.
Discontinue use and consult a physician if no improvement is seen within 3-5 days, if the condition worsens, or if signs of irritation or allergic reaction appear.
Avoid application to large areas of damaged skin, severe burns, or chronic ulcers without medical supervision due to increased risk of systemic absorption and toxicity.
Do not apply in or near the eyes; if accidental contact occurs, rinse thoroughly with water.
Adverse Reactions
From the immune system rarely – allergic reactions (if there is a history of allergic reactions to Neomycin, cross-allergy to other aminoglycosides is possible in 50% of cases); frequency unknown – increased sensitivity to various substances, including Neomycin (usually observed when used in the therapy of chronic dermatoses), in some cases allergic reactions may appear as a lack of effect from the therapy.
From the nervous system frequency unknown – damage to the vestibular nerve, neuromuscular blockade.
From the organ of hearing and labyrinthine disorders frequency unknown – ototoxicity.
From the skin and subcutaneous tissues rarely – allergic reactions manifesting as contact dermatitis, allergic reaction to Neomycin; frequency unknown – allergic reactions in the form of redness and dryness of the skin, skin rashes and itching (with prolonged use).
From the kidneys and urinary tract frequency unknown – nephrotoxicity.
If any of the side effects listed in the instructions get worse, or you notice any other side effects not listed in the instructions, the patient should immediately inform the doctor.
Contraindications
Hypersensitivity to bacitracin, neomycin or other aminoglycosides; extensive skin lesions (risk of developing an ototoxic effect accompanied by hearing loss); severe excretory function impairment due to cardiac or renal failure in patients with pre-existing lesions of the vestibular and cochlear systems in cases where absorption of active substances is possible; infections of the external auditory canal with perforation of the eardrum; simultaneous use with systemic aminoglycoside antibiotics (risk of cumulative toxicity); not for use in the treatment of eye infections.
With caution
Patients with impaired liver and/or kidney function, acidosis, severe myasthenia gravis or other neuromuscular diseases.
Use in Pregnancy and Lactation
Use during pregnancy and breastfeeding is possible only after consultation with a doctor if the intended benefit to the mother outweighs the potential risk to the fetus or infant.
It should be remembered that Neomycin, like all antibiotics of the aminoglycoside group, can cross the placental barrier. With systemic use of aminoglycoside antibiotics in high doses, intrauterine hearing loss in the fetus has been described.
Use in Hepatic Impairment
Should be used with caution in patients with impaired liver function.
Use in Renal Impairment
Should be used with caution in patients with impaired renal function.
Pediatric Use
If use in children is necessary, a doctor should be consulted beforehand.
Geriatric Use
No dose adjustment is required for elderly patients.
Special Precautions
Since the risk of toxic effects increases with reduced liver and/or kidney function, patients with hepatic and/or renal insufficiency should undergo blood and urine tests along with audiometric testing before and during therapy with this combination.
If the components of the combination are absorbed, attention should be paid to the potential blockade of neuromuscular conduction, especially in patients with acidosis, myasthenia gravis or other neuromuscular diseases. In this case, calcium preparations or neostigmine methylsulfate may prevent the development of such blockades.
During long-term treatment, attention should be paid to the possible growth of resistant microorganisms. In such situations, appropriate treatment tactics should be chosen.
In case of use in children, patients with impaired liver and kidney function, as well as with a large area of the treated surface, prolonged use and deep skin lesions, a doctor should be consulted beforehand.
If allergic reactions and superinfection develop, use should be discontinued.
Drug Interactions
With systemic absorption of the active components of the combination, simultaneous use of cephalosporins or aminoglycoside antibiotics may increase the likelihood of nephrotoxic reactions.
Simultaneous use with a combination of diuretics such as ethacrynic acid or furosemide may provoke oto- and nephrotoxic effects.
Absorption of the active components of the combination may enhance the phenomena of neuromuscular conduction blockade in patients receiving opioid analgesics, anesthetics and/or muscle relaxants.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
250 IU+5000 IU/1 g ointment for external use: 10 g, 15 g, 20 g, 25 g, 30 g, 35 g, 40 g, 50 g, 60 g, 70 g, 80 g, or 100 g tubes
Marketing Authorization Holder
Tula Pharmaceutical Factory, LLC (Russia)
Dosage Form
| Baciderm | 250 IU+5000 IU/1 g ointment for external use: 10 g, 15 g, 20 g, 25 g, 30 g, 35 g, 40 g, 50 g, 60 g, 70 g, 80 g, or 100 g tubes |
Dosage Form, Packaging, and Composition
Ointment for external use yellowish, homogeneous, with a faint characteristic odor.
| 1 g | |
| Bacitracin (in the form of bacitracin zinc*) | 250 IU (0.00416 g) |
| Neomycin (in the form of neomycin sulfate*) | 5000 IU (0.00746 g) |
* The quantitative content in grams depends on the initial activity of the active substances.
The content of active substances is indicated based on the activity: 60 IU/mg of bacitracin in terms of bacitracin zinc; 670 IU/mg of neomycin in terms of neomycin sulfate.
Excipients: lanolin – 0.11 g, white soft paraffin – up to 1 g.
10 g – aluminum tubes (1) – cardboard packs.
15 g – aluminum tubes (1) – cardboard packs.
20 g – aluminum tubes (1) – cardboard packs.
25 g – aluminum tubes (1) – cardboard packs.
30 g – aluminum tubes (1) – cardboard packs.
35 g – aluminum tubes (1) – cardboard packs.
40 g – aluminum tubes (1) – cardboard packs.
50 g – aluminum tubes (1) – cardboard packs.
60 g – aluminum tubes (1) – cardboard packs.
70 g – aluminum tubes (1) – cardboard packs.
80 g – aluminum tubes (1) – cardboard packs.
100 g – aluminum tubes (1) – cardboard packs.
Powder for external use 250 IU/1 g+5000 IU/1 g: bottle 10 g, 15 g or 20 g with dispenser
Marketing Authorization Holder
Tula Pharmaceutical Factory, LLC (Russia)
Dosage Form
| Baciderm | Powder for external use 250 IU/1 g+5000 IU/1 g: bottle 10 g, 15 g or 20 g with dispenser |
Dosage Form, Packaging, and Composition
Powder for external use white or yellowish in color, finely dispersed.
| 1 g | |
| Bacitracin (in the form of bacitracin zinc*) | 250 IU (0.00416 g) |
| Neomycin (in the form of neomycin sulfate*) | 5000 IU (0.00746 g) |
* The quantitative content in grams depends on the initial activity of the active substances.
The content of active substances is indicated based on the activity: 60 IU/mg of bacitracin in terms of bacitracin zinc; 670 IU/mg of neomycin in terms of neomycin sulfate.
Excipients: corn starch – 0.987 g.
10 g – bottles (1) with a dispenser – cardboard packs.
15 g – bottles (1) with a dispenser – cardboard packs.
20 g – bottles (1) with a dispenser – cardboard packs.
OKI, sachets 80mg 2g, 12pcs
Picamilon pills 50mg, 60pcs
Ingavirin capsules 90mg, 10pcs
Belosalic, ointment, 30g
Mildronate capsules 500mg, 90pcs
Phenibut-Vertex pills 250mg, 20pcs
Daivobet, ointment, 30g
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Nootropil pills 800mg, 30pcs
Kagocel pills 12mg, 30pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Cortexin, 10mg, 5ml, 10pcs
Belosalic, lotion solution for external use spray 100ml
Arbidol, capsules 100mg, 40pcs
Fenotropil pills 100mg, 60pcs
Actovegin pills 200mg, 50pcs 